San Francisco Marriott Marquis
Yerba Buena Ballroom, Salon 8
Lower B2 Level
780 Mission Street
San Francisco, CA 94103
6:30 PM: Registration and Dinner
7:00 PM: Welcome and Introduction: Mapping the Present and Future of Care in Advanced Pancreatic Cancer
A profile of the current role of chemotherapy advances in pancreatic cancer, future innovations with targeted and immunotherapy options, and professional practice patterns/polling results
7:10 PM: MasterClass 1: A Close Look at Advances in Cytotoxic Backbones in Pancreatic Cancer
An exploration of the science behind newer chemotherapy platforms in pancreatic cancer and the insight driving a more patient-oriented, sequential approach to selecting therapy
7:40 PM: Hearing the Patient Voice: Treatment Decisions and the Care Experience
In collaboration with Let’s Win/Lustgarten Foundation, a session devoted to highlighting the patient’s perspectives on current treatment, clinical trials, and future innovations in pancreatic cancer care
7:50 PM: MasterClass 2: New Frontiers, Novel Agents, and Combinations Across Pancreatic Cancer
A tour of the future of pancreatic cancer management, from targeting the cell microenvironment to immune options and the role of clinical trials in driving potent anticancer combination strategies
8:20 PM: Q&A and Symposium Summary
8:30 PM: Adjourn
Advanced pancreatic cancer carries a fearsome reputation as a challenging, chemoresistant disease, due in part to its aggressive nature and the unique biology of the pancreatic cancer cell. But despite the limited success of historical chemotherapy options, it’s clear that this dire picture is changing. Novel, recently validated cytotoxic platforms are demonstrating clinical benefits when used in an optimized, sequential fashion across the treatment continuum; in addition, newer agents targeting aspects of the pancreatic cancer cell, such as the stroma, the immune microenvironment, or therapeutically relevant mutations, are in rapid development, with most evidence suggesting they may be effectively combined with innovative chemotherapy platforms. PeerView’s latest interactive “MasterClass” symposium will offer oncology professionals a deep dive into the science and practical application of these advancements, while also—in collaboration with Let’s Win/Lustgarten Foundation—showcasing the voice and perspectives of patients with pancreatic cancer. Join us in San Francisco for this compelling live event.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with pancreatic cancer.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.
Release and Expiration Date: January 19, 2018
Time to Complete: 90 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.
Andrew H. Ko, MD
Professor of Clinical Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California
Andrew E. Hendifar, MD, MPH
Co-Director, Pancreas Oncology
Gastrointestinal and Neuroendocrine Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California
George P. Kim, MD
Consultant, 21st Century Oncology
University of Florida Health
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by independent educational grants from AstraZeneca, Halozyme Therapeutics, and Ipsen Biopharmaceuticals, Inc.
This CME activity has been developed in collaboration with Let’s Win!, an online community (letswinpc.org) for sharing information about innovative, science-based treatments for Pancreatic Cancer. Let’s Win! is an initiative supported by the Lustgarten Foundation.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
We invite you to attend our other symposium while at the ASCO-GU. For our Thursday dinner symposium, register here: peerview.com/HCC18.